{"id":2495,"date":"2024-09-16T15:00:35","date_gmt":"2024-09-16T13:00:35","guid":{"rendered":"https:\/\/vbhi-institute.org\/?p=2495"},"modified":"2024-09-16T15:00:35","modified_gmt":"2024-09-16T13:00:35","slug":"new-biological-fingerprint-for-cerebral-small-vessel-disease","status":"publish","type":"post","link":"https:\/\/vbhi-institute.org\/en\/new-biological-fingerprint-for-cerebral-small-vessel-disease\/","title":{"rendered":"New biological fingerprint for cerebral small vessel disease"},"content":{"rendered":"
[vc_row][vc_column][vc_column_text css=”” el_class=”intro”]Cerebral small vessel disease (cSVD) is a leading cause of stroke and dementia with no specific mechanism-based treatment. Genomics can provide a strong foundation for mechanistic studies and drug target discovery. While large-scale proteomic investigations have recently been conducted for stroke and dementia, with promising findings, studies on proteomics of cSVD have been conducted on limited sets of proteins, in small studies of European ancestry (N\u2009<\u20095,000), and in plasma only14\u201318. The researchers hypothesize that, while plasma may enable easy-access biomarker measurements, CSF, the fluid circulating in perivascular spaces, could reveal a more accurate biological fingerprint of cSVD.[\/vc_column_text][vc_column_text css=””]\n

Methods<\/h2>\n

The researchers including St\u00e9phanie Debette<\/a>, director of the VBHI, Agust\u00edn Riuz<\/a>, member of the VBHI Scientific Advisory Board and David-Alexandre Tregou\u00ebt<\/a>, member of the VBHI Board of Director, used Mendelian randomization to combine a unique cerebrospinal fluid (CSF) and plasma pQTL resource with the latest European-ancestry GWAS of MRI-markers of cSVD (white matter hyperintensities, perivascular spaces).<\/p>\n

They describe a new biological fingerprint of 49 protein-cSVD associations, predominantly in the CSF.<\/p>\n

They implemented a multipronged follow-up, across :<\/p>\n